Some clinical lessons from one Blood and Marrow Transplantation Unit in Medellin, Colombia

Authors

  • Francisco CUELLAR-AMBROSI clinica León XIII - IPS U de Antioquia
  • Mónica Monsalve Moreno MD clinica León XIII - IPS U de Antioquia
  • Beatriz Urrego Grisales
  • Jorge Cuervo Sierra
  • Guillermo Gaviria Cardona
  • Vanessa Naranjo Serrano
  • Carolina Cuéllar-Garcia

DOI:

https://doi.org/10.46765/2675-374X.2021v2n2p102

Keywords:

HSCT, Pegfiltrastim MOBILIZATION, Non_Cryopreservation, Non- IRRADIATION BLOOD

Abstract

After more than 60 years of the first successful bone marrow transplant (BMT) by D.E. Thomas for the treatment of hematological malignant diseases and more than 46 years since the first bone marrow transplant by Alberto Restrepo-Mesa in Medellin-Colombia for the treatment of a female triplet patient with paroxysmal nocturnal hemoglobinuria and aplastic anemia, in Colombia only around 750 bone marrow transplants are performed annually.

With the experience accumulated during these years by each one of us, the León XIII Clinic of the Universidad de Antioquia began the hematopoietic stem cell transplantation (HSCT) program for adults in 2014. In this review, we report some clinical lessons drawn from the different phases of the HSCT in 109 adult patients with hematological malignancies. The progression-free survival (PFS) and the five-year overall survival (OS) were for autologous stem cell transplantation (ASCT) (87% and 70%), allogeneic stem cell transplantation (Allo SCT) (50% and 40%) and haploidentical stem cell transplantation (Haplo SCT) (25% and 18%) respectively.

Downloads

Published

07/16/2021

How to Cite

CUELLAR-AMBROSI, F., Monsalve Moreno MD, M., Urrego Grisales, B., Cuervo Sierra, J., Gaviria Cardona, G., Naranjo Serrano, V., & Cuéllar-Garcia, C. (2021). Some clinical lessons from one Blood and Marrow Transplantation Unit in Medellin, Colombia. JOURNAL OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY, 2(2), p102. https://doi.org/10.46765/2675-374X.2021v2n2p102

Issue

Vol. 2 No. 2 (2021): Journal of Bone Marrow Transplantation and Cellular Therapy

Section

Original article

License

License and Copyright Policy

The Journal of Bone Marrow Transplantation and Cellular Therapy (JBMTCT) adopts an open access policy, ensuring that all published articles are freely available to the public without restrictions.

  1. License

    • All articles published in JBMTCT are licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0).
    • This license permits anyone to:
      • Share: Copy and redistribute the material in any medium or format.
      • Adapt: Remix, transform, and build upon the material for any purpose, even commercially.
    • The only requirement is that appropriate credit is given to the original authors and source, a link to the license is provided, and any changes made are indicated.

    More information about the license can be found here: Creative Commons Attribution 4.0 International License.

  2. Authors’ Rights

    • Authors retain the copyright to their work.
    • Authors grant JBMTCT the right to publish the work and make it openly accessible online.
    • Authors are free to:
      • Distribute the published version of their article (e.g., post it on personal websites or institutional repositories).
      • Use the article in future works, presentations, or derivative publications, as long as the original publication in JBMTCT is properly acknowledged.

  3. No Embargo

    • There is no embargo period; articles are made freely available immediately upon publication.

  4. Ethical Use

    • Users of JBMTCT articles must ensure proper citation of the authors and the journal.
    • Articles must not be used in ways that violate ethical or legal standards.

  5. Disclaimer

    • While JBMTCT aims to ensure the accuracy and reliability of published content, the journal and its editors are not responsible for the consequences of its use.

For any questions regarding our licensing terms, please contact us at: journalbmtct@sbtmo.org.br 

JBMTCT is committed to the principles of open access to advance knowledge and scientific collaboration.